Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study

Abstract

Home administration of s.c. bortezomib is cost-effective and is preferred by myeloma patients compared with hospital administration.

Posttransplant maintenance therapy in multiple myeloma: the changing landscape

“…No increased risk of SPMs was seen in bortezomib trials, but its injectable form could be a limit for long-term maintenance therapy. However, subcutaneous administration is well tolerated 48 and home administration is feasible 49 and could further improve patients' acceptance, particularly in the setting of a long-term maintenance therapy. Recently, an oral proteasome inhibitors, namely ixazomib, have emerged as efficacious for MM in the relapsed, refractory setting 50 that is also being investigated for maintenance use.…”

Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice

“…Interpretation of data regarding resource utilization is limited due to differences in clinical practice and healthcare systems between the different countries participating in eVOBS. Although patients appeared to be managed predominantly in the outpatient setting in eVOBs, the subsequent introduction of subcutaneous bortezomib has enabled home administration which is cost‐saving as well as more cost‐effective and is preferred by patients . Furthermore, the recent advent of all‐oral regimens such as lenalidomide‐dexamethasone‐ixazomib has also increased patient convenience and the potential for home‐based management.…”

“…Although patients appeared to be managed predominantly in the outpatient setting in eVOBs, the subsequent introduction of subcutaneous bortezomib has enabled home administration which is cost-saving as well as more cost-effective and is preferred by patients. [38][39][40] Furthermore, the recent advent of all-oral regimens such as lenalidomidedexamethasone-ixazomib 41 has also increased patient convenience and the potential for home-based management.…”

Nursing support during treatment of multiple myeloma with proteasome inhibitors

“…A recent prospective study explored the possibility of patients self-administering bortezomib at home (Lassalle et al 2015). Home administration was found to be more cost-effective than administration at an outpatient clinic and improved quality of life in 84% of participants, while 98% preferred selfadministering the drug at home (Lassalle et al 2015).…”

“…A recent prospective study explored the possibility of patients self-administering bortezomib at home (Lassalle et al 2015). Home administration was found to be more cost-effective than administration at an outpatient clinic and improved quality of life in 84% of participants, while 98% preferred selfadministering the drug at home (Lassalle et al 2015). If self-administration becomes more common, nurses are likely to play a central role in advising and supervising patients who adopt this approach; for example it will be important to advise patients that erythema at the injection site may occur (Ng et al 2015).…”